Immix Biopharma, Inc. (IMMX) vs 908 Devices Inc. (MASS)
A side-by-side comparison of Immix Biopharma, Inc. and 908 Devices Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
IMMX
Immix Biopharma, Inc.
$9.64HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
MASS
908 Devices Inc.
$12.33HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — IMMX vs MASS
growth of $100 · dividends reinvested · last 5yIMMX +176.0% (+22.5%/yr)MASS -46.5% (-11.8%/yr)IMMX compounded faster over this window
Log scale — wide-divergence pair
IMMX MASS
IMMX vs MASS: by the numbers
- •IMMX is the larger company ($524M vs $506M market cap).
- •Both run net losses; IMMX's is the smaller (0.00% vs -56.68% net margin).
Metrics side by side
Valuation
| Metric | IMMX | MASS |
|---|---|---|
| P/S ratio | N/A | 8.31 |
| P/B ratio | 2.29 | 3.99 |
| FCF yield | N/A | 0.10% |
Profitability
| Metric | IMMX | MASS |
|---|---|---|
| Gross margin | 0.00% | 49.79% |
| Operating margin | 0.00% | -46.01% |
| Net margin | 0.00% | -56.68% |
| ROE | -17.44% | -27.20% |
| ROIC | -18.20% | -18.90% |
Growth (annualized)
| Metric | IMMX | MASS |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 18.92% |
| Total return CAGR (5Y) | N/A | -17.66% |
Go deeper
Dig into the metrics
Immix Biopharma ROE908 Devices ROEImmix Biopharma operating margin908 Devices operating marginImmix Biopharma revenue growth908 Devices revenue growthImmix Biopharma free cash flow908 Devices free cash flow
Immix Biopharma & 908 Devices appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.